Med­i­cines Co scores FDA OK for new an­tibi­ot­ic, now up on the auc­tion block

The Med­i­cines Com­pa­ny’s in­fec­tious dis­ease busi­ness just got more valu­able.

The FDA has come through with an ac­cel­er­at­ed ap­proval of Vabomere — the com­bo of vabor­bac­tam, a new be­ta-lac­ta­mase in­hibitor, and meropen­em, the lead­ing car­bapen­em — which should help its deals team as the com­pa­ny hunts up a buy­er for all or part of that busi­ness group.

Tech­ni­cal­ly, the OK went to Rem­pex, which The Med­i­cines Com­pa­ny bought in 2013 for up to $474 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.